NasdaqGS:SRRKBiotechs
The Bull Case For Scholar Rock (SRRK) Could Change Following Dual-Track Apitegromab BLA Manufacturing Strategy
Scholar Rock reported second-quarter 2026 results showing a net loss of US$109.9 million and a basic loss per share of US$0.84, alongside updates on its apitegromab program for spinal muscular atrophy (SMA) and broader pipeline progress.
A key development was the advancement of apitegromab’s Biologics License Application with two independent fill‑finish facilities, giving Scholar Rock multiple manufacturing paths toward potential FDA approval while it prepares for an immediate U.S. launch...